Asia Pacific Non Small Cell Lung Cancer Diagnostics Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2021 –2028 |
 Market Size (Base Year) |
USD 291.14 Million |
 Market Size (Forecast Year) |
USD 865.62 Million |
 CAGR |
% |
| Major Markets Players |
亚太非小细胞肺癌诊断市场，按癌症类型（肺腺癌（LUAD）、肺鳞状细胞癌（LUSC）、大细胞癌等）、产品（试剂和试剂盒、仪器和服务和软件）、测试（影像测试、分子测试、活检、痰细胞学、胸腔穿刺术、免疫组织化学等）、最终用户（医院、临床实验室、学术界等）国家（中国、泰国、澳大利亚、日本、韩国、新加坡、马来西亚、印度尼西亚、菲律宾、印度和亚太其他地区）行业趋势和预测到 2028 年。
市场分析与洞察：亚太地区非小细胞肺癌诊断市场
亚太非小细胞肺癌诊断市场预计将从 2020 年的 2.9114 亿美元增至 2028 年的 8.6562 亿美元，在 2021 年至 2028 年的预测期内以 14.6% 的复合年增长率稳步增长。
非小细胞肺癌是一种在肺组织中形成恶性细胞或癌细胞的疾病。这些细胞有不同的类型，每种类型的癌细胞都以特定的方式生长和扩散。非小细胞肺癌 (NSCLC) 类型包括鳞状细胞癌、大细胞癌和腺癌。鳞状细胞癌的癌症形成于肺内壁薄而扁平的细胞中，称为表皮样癌。大细胞癌始于几种类型的大细胞。腺癌始于肺泡内壁细胞，并产生粘液等物质。非小细胞肺癌 (NSCLC) 的主要风险之一是吸烟，症状包括持续咳嗽和呼吸急促。人们使用各种测试来诊断和检查癌症阶段，例如影像学测试、分子测试、活检等。诊断对于及时发现疾病至关重要，这样才能对患者进行适当的治疗。
推动非小细胞肺癌诊断市场增长的因素包括使用人工智能和机器学习来改进诊断程序，再加上更容易患非小细胞肺癌的老年人口数量的增加，而市场竞争激烈和由于 COVID-19 大流行导致的供应链中断可能会对非小细胞肺癌诊断市场的增长提出挑战。
Moreover, the rise in healthcare expenditure in developing countries and the increase in the adoption of new technology to diagnose non-small cell lung cancer will create huge opportunities for the global non-small cell lung cancer diagnostics market. On the other hand, high competition in the market and disturbed supply chain due to the COVID-19 pandemic are expected to challenge the global non-small cell lung cancer diagnostics market.
The non-small cell lung cancer diagnostics market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the non-small cell lung cancer diagnostics market scenario, contact Data Bridge Market Research for an Analyst Brief. Our team will help you create a revenue impact solution to achieve your desired goal.
Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market Scope and Market Size
The Asia-Pacific non-small cell lung cancer diagnostics market is segmented into four notable segments based on the cancer type, products, test, and end-user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of cancer type, the Asia-Pacific non-small cell lung cancer diagnostics market is segmented into lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), large cell carcinoma, and others. In 2021, the lung adenocarcinoma (LUAD) segment is expected to dominate the non-small cell lung cancer diagnostics market due to the increasing number of adenocarcinoma lung cancer patients in the world.
- On the basis of products, the Asia-Pacific non-small cell lung cancer diagnostics market is segmented into reagents and kits, instruments and services, and software. In 2021, the instrument is expected to dominate the non-small cell lung cancer diagnostics market due to the increasing demand for high technological instruments to diagnose non-small cell lung cancer with accuracy.
- On the basis of the test, the Asia-Pacific non-small cell lung cancer diagnostics market is a segmented imaging test, molecular test, biopsy, sputum cytology, thoracentesis, immunohistochemistry, and others. In 2021, the molecular test segment is expected to dominate the non-small cell lung cancer diagnostics market due to the growing need for molecular tests for lung cancer diagnosis to provide proper treatment to patients.
- On the basis of end-user, the Asia-Pacific non-small cell lung cancer diagnostics market is segmented into hospitals, clinical laboratories, academics, and others. In 2021, the clinical laboratories segment is expected to dominate the non-small cell lung cancer diagnostics market due to the increase in research on non-small cell lung cancer in clinical laboratories.
Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market: Country Level Analysis
Asia-Pacific non-small cell lung cancer diagnostics market is segmented into four notable segments based on the cancer type, products, test, and end-user.
Countries covered in the Asia-Pacific Non-small cell lung cancer diagnostics market report are China, Thailand, Australia, Japan, South Korea, Singapore, Malaysia, Indonesia, Philippines, India, and the Rest of Asia-Pacific.
The products segment in the China region is expected to grow with the highest share in the forecast period of 2021 to 2028 because of the increase in demand for diagnosis instruments to diagnose non-small cell lung cancer patients. The products segment in India is dominating the Asia-Pacific market owing to increased healthcare expenditure. The Philippines is leading the growth of the Asia-Pacific market for products segment is dominating in this country due to rising healthcare expenditure.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.
Growing Strategic Activities By Major Market Players To Enhance The Awareness For Non-Small Cell Lung Cancer Diagnostics, Is Boosting The Market Growth Of Non-Small Cell Lung Cancer Diagnostics Market.
The non-small cell lung cancer diagnostics market also provides you with a detailed market analysis for every country's growth in a particular market. Additionally, it provides detailed information regarding the market players' strategy and their geographical presence. The data is available for the historical period 2010 to 2019.
Competitive Landscape and Asia-Pacific Non-small cell lung cancer diagnostics Market Share Analysis
亚太非小细胞肺癌诊断市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、印度业务、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用主导地位和技术生命线曲线。以上提供的数据点仅与公司对非小细胞肺癌诊断市场的关注有关。
非小细胞肺癌诊断市场的一些主要参与者包括雅培实验室、F. Hoffmann-La Roche Ltd、安捷伦科技公司、QIAGEN、赛默飞世尔科技公司、Quest Diagnostics Incorporated、NeoGenomics Laboratories, Inc.、NanoString、杨森制药公司、Inivata Ltd、bioMérieux SA、Biotheranostics、OncoCyte Corporation Inc.、通用电气公司、Eckert & Ziegler、Dr. Lal PathLabs、RIVERAIN TECHNOLOGIES、PlexBio Co., Ltd、Oncimmune、Biodesix 以及其他国内参与者。DBMR 分析师了解竞争优势并为每个竞争对手分别提供竞争分析。
全球各地的公司也发起了许多合同、协议和发布，这也加速了非小细胞肺癌诊断市场的发展。
例如，
- 2021 年 3 月，安捷伦科技公司以 5.5 亿美元收购了 Resolution Bioscience，以加强其基于新一代测序 (NGS) 的肿瘤学解决方案业务
- 2021 年 5 月，QIAGEN 推出了经 FDA 批准的 therascreen KRAS RGQ PCR 试剂盒，该试剂盒可帮助患者识别非小细胞肺癌 (NSCLC)
- 2020年6月，罗氏公司推出自动化数字病理算法uPath PD-L1（SP263）图像分析，用于诊断非小细胞肺癌（NSCLC），提高诊断治疗的速度和准确性
市场参与者的合作、产品发布、业务扩展、奖励和认可、合资企业等策略正在增强公司在非小细胞肺癌诊断市场的影响力，这也为公司的利润增长带来了好处。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 CANCER TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 ROLE OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING
4.2 PRODUCT AND BRAND ANALYSIS: ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET
4.3 ABBOTT LABORATORIES-
4.4 F. HOFFMANN-LA ROCHE LTD -
4.5 AGILENT TECHNOLOGIES, INC.
4.6 QIAGEN
4.7 THERMO FISHER SCIENTIFIC, INC
4.8 QUEST DIAGNOSTICS INCORPORATED
4.9 NEOGENOMICS LABORATORIES, INC.
4.1 NANOSTRING
4.11 JANSSEN PHARMACEUTICAL NV
4.12 INIVATA LTD
4.13 BIOMÉRIEUX SA
4.14 BIOTHERANOSTICS, INC.
4.15 ONCOCYTE CORPORATION
4.16 ECKERT & ZIEGLER
4.17 GENERAL ELECTRIC COMPANY
4.18 DR LAL PATHLABS
4.19 RIVERAIN TECHNOLOGIES
4.2 PLEXBIO CO.,LTD
4.21 BIODESIX
4.22 ONCIMMUNE
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 RISE IN PREVALENCE OF LUNG CANCER ACROSS THE WORLD
5.1.2 GROWING NUMBER OF GERIATRIC POPULATION THAT IS MORE SUSCEPTIBLE TO NON-SMALL CELL LUNG CANCER
5.1.3 GROWING COLLABORATION PARTNERSHIP AND AGREEMENT BY THE KEY PLAYERS
5.1.4 GROWING USAGE OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING TO IMPROVE THE DIAGNOSTIC PROCEDURES
5.1.5 INCREASING PREVALENCE OF UNHEALTHY LIFESTYLE THAT POSES A SERIOUS RISK OF LUNG CANCER
5.1.6 GROWING PRODUCT LAUNCHES
5.2 RESTRAINTS
5.2.1 CHALLENGES ASSOCIATED WITH BRAND EQUITY
5.2.2 MAINTAINING HIGH LEVEL OF EXPERTISE FOR DIAGNOSIS PURPOSE
5.3 OPPORTUNITIES
5.3.1 RISING HEALTHCARE EXPENDITURE IN DEVELOPING REGION
5.3.2 INCREASING ADOPTION OF NEW TECHNOLOGY TO DIAGNOSE NON-SMALL CELL LUNG CANCER
5.3.3 INCREASE IN THE NUMBER OF APPROVALS FOR NON-SMALL CELL LUNG CANCER PRODUCTS
5.4 CHALLENGES
5.4.1 HIGH COMPETITION AMONG MARKET PLAYERS
5.4.2 DISTURBED SUPPLY CHAIN DUE TO COVID-19
6 IMPACT OF COVID-19 ON THE ASIA-PACIFIC NON SMALL CELL LUNG CANCER DIAGNOSTIC MARKET
6.1 IMPACT ON DEMAND
6.2 IMPACT ON SUPPLY CHAIN
6.3 IMPACT ON PRICE
6.4 CONCLUSION
7 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE
7.1 OVERVIEW
7.2 LUNG ADENOCARCINOMA (LUAD)
7.3 LUNG SQUAMOUS CELL CARCINOMA (LUSC)
7.4 LARGE CELL CARCINOMA
7.5 OTHERS
8 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT
8.1 OVERVIEW
8.2 INSTRUMENTS
8.3 REAGENTS AND KITS
8.3.1 LUNG CANCER ASSAY KIT
8.3.2 MUTATION KIT
8.3.3 EXTRACTION KIT
8.3.4 SAMPLE PREPARATION KIT
8.3.5 SOLID TUMOUR KIT
8.3.6 OTHERS
8.4 SERVICES AND SOFTWARES
9 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST
9.1 OVERVIEW
9.2 MOLECULAR TEST
9.2.1 RT-PCR
9.2.2 NEXT-GENERATION SEQUENCING (NGS)
9.2.3 DNA MICROARRAY
9.2.4 NEXT GENERATION CAPTURE
9.2.5 LAB-ON -A CHIP (LOAC)
9.2.6 MULTIPLEX CONVENTIONAL
9.2.7 PROTEIN MICROARRAY
9.2.8 OTHER
9.3 IMAGING TEST
9.3.1 PISITRON EMISSION TOMOGRAPHY (PET) SCAN
9.3.2 MAGNETIC RESONANCE IMAGING (MRI) SCAN
9.3.3 CT SCAN
9.3.4 BONE SCAN
9.3.5 OTHERS
9.4 IMMUNOHISTOCHEMISTRY
9.5 BIOPSY
9.6 SPUTUM CYTOLOGY
9.7 THORECENTESIS
9.8 OTHERS
10 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER
10.1 OVERVIEW
10.2 CLINICAL LABORATORIES
10.3 HOSPITAL
10.4 ACADEMICS
10.5 INSTITUTES AND RESEARCH CENTERS
11 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION
11.1 ASIA-PACIFIC
11.1.1 CHINA
11.1.2 JAPAN
11.1.3 INDIA
11.1.4 SOUTH KOREA
11.1.5 AUSTRALIA
11.1.6 MALAYSIA
11.1.7 THAILAND
11.1.8 INDONESIA
11.1.9 SINGAPORE
11.1.10 PHILIPPINES
11.1.11 REST OF ASIA-PACIFIC
12 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 ABBOTT LABORATORIES
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENT
14.2 F. HOFFMANN-LA ROCHE LTD
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENTS
14.3 QUEST DIAGNOSTICS INCORPORATED
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENT
14.4 GENERAL ELECTRIC COMPANY
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENTS
14.5 NANOSTRING
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COMPANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENT
14.6 AGILENT TECHNOLOGIES, INC.
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENTS
14.7 BIODESIX
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENT
14.8 BIOMERIEUX SA
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
14.8.4 RECENT DEVELOPMENT
14.9 BIOTHERANOSTICS
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT DEVELOPMENTS
14.1 DR LAL PATHLABS
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENT
14.11 ECKERT & ZIEGLER
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENT
14.12 INIVATA LTD
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENT
14.13 JANSSEN PHARMACEUTICAL NV
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENT
14.14 NEOGENOMICS LABORATORIES, INC.
14.14.1 COMPANY SNAPSHOT
14.14.2 REVENUE ANALYSIS
14.14.3 PRODUCT PORTFOLIO
14.14.4 RECENT DEVELOPMENTS
14.15 ONCIMMUNE
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENT
14.16 ONCOCYTE CORPORATION
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENTS
14.17 PLEXIBIO CO LTD
14.17.1 COMPANY SNAPSHOT
14.17.2 REVENUE ANALYSIS
14.17.3 PRODUCT PORTFOLIO
14.17.4 RECENT DEVELOPMENT
14.18 QIAGEN
14.18.1 COMPANY SNAPSHOT
14.18.2 REVENUE ANALYSIS
14.18.3 PRODUCT PORTFOLIO
14.18.4 RECENT DEVELOPMENTS
14.19 RIVERAIN TECHNOLOGIES
14.19.1 COMPANY SNAPSHOT
14.19.2 PRODUCT PORTFOLIO
14.19.3 RECENT DEVELOPMENT
14.2 THERMO FISHER SCIENTIFIC INC.
14.20.1 COMPANY SNAPSHOT
14.20.2 REVENUE ANALYSIS
14.20.3 PRODUCT PORTFOLIO
14.20.4 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
表格列表
LIST OF TABLES
TABLE 1 AGING WORLD POPULATION
TABLE 2 U.K. X RAY DEMAND 2018
TABLE 3 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 4 ASIA-PACIFIC LUNG ADENOCARCINOMA (LUAD) IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 ASIA-PACIFIC LUNG SQUAMOUS CELL CARCINOMA (LUSC) IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 ASIA-PACIFIC LARGE CELL CARCINOMA IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 ASIA-PACIFIC OTHERS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 9 ASIA-PACIFIC INSTRUMENTS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 ASIA-PACIFIC REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 ASIA-PACIFIC REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 12 ASIA-PACIFIC SERVICES AND SOFTWARES IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 14 ASIA-PACIFIC MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 ASIA-PACIFIC MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 16 ASIA-PACIFIC IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 ASIA-PACIFIC IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 18 ASIA-PACIFIC IMMUNOHISTOCHEMISTRY IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 ASIA-PACIFIC BIOPSY IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2020
TABLE 20 ASIA-PACIFIC SPUTUM CYTOLOGY IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 ASIA-PACIFIC THORECENTESIS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 ASIA-PACIFIC OTHERS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 24 ASIA-PACIFIC CLINICAL LABORATORIES IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 ASIA-PACIFIC HOSPITAL IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 26 ASIA-PACIFIC ACADEMICS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 ASIA-PACIFIC INSTITUTES AND RESEARCH CENTERS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 29 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 30 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 31 ASIA-PACIFIC REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 32 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 33 ASIA-PACIFIC IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 34 ASIA-PACIFIC MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 35 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 36 CHINA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 37 CHINA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 38 CHINA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 39 CHINA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 40 CHINA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 41 CHINA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 42 CHINA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 43 JAPAN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 44 JAPAN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 45 JAPAN REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 46 JAPAN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 47 JAPAN IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 48 JAPAN MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 49 JAPAN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 50 INDIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 51 INDIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 52 INDIA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 53 INDIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 54 INDIA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 55 INDIA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 56 INDIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 57 SOUTH KOREA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 58 SOUTH KOREA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 59 SOUTH KOREA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 60 SOUTH KOREA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 61 SOUTH KOREA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 62 SOUTH KOREA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 63 SOUTH KOREA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 64 AUSTRALIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 65 AUSTRALIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 66 AUSTRALIA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 67 AUSTRALIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 68 AUSTRALIA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 69 AUSTRALIA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 70 AUSTRALIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 71 MALAYSIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 72 MALAYSIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 73 MALAYSIA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 74 MALAYSIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 75 MALAYSIA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 76 MALAYSIA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 77 MALAYSIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 78 THAILAND NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 79 THAILAND NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 80 THAILAND REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 81 THAILAND NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 82 THAILAND IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 83 THAILAND MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 84 THAILAND NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 85 INDONESIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 86 INDONESIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 87 INDONESIA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 88 INDONESIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 89 INDONESIA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 90 INDONESIA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 91 INDONESIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 92 SINGAPORE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 93 SINGAPORE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 94 SINGAPORE REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 95 SINGAPORE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 96 SINGAPORE IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 97 SINGAPORE MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 98 SINGAPORE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 99 PHILIPPINES NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 100 PHILIPPINES NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 101 PHILIPPINES REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 102 PHILIPPINES NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 103 PHILIPPINES IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 104 PHILIPPINES MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 105 PHILIPPINES NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 106 REST OF ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
图片列表
LIST OF FIGURES
FIGURE 1 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: DBMR VENDOR SHARE ANALYSIS
FIGURE 9 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 10 RISE IN THE GERIATRIC POPULATION THAT IS MORE SUSCEPTIBLE TO NON-SMALL CELL LUNG CANCER IS EXPECTED TO DRIVE THE ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 11 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET IN 2021 & 2028
FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET
FIGURE 13 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2020
FIGURE 14 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020
FIGURE 15 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2020
FIGURE 16 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2020
FIGURE 17 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: SNAPSHOT (2020)
FIGURE 18 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2020)
FIGURE 19 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 20 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2020 & 2028)
FIGURE 21 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: BY LUNG CANCER TYPE (2021 & 2028)
FIGURE 22 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2020 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
